Hikal has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its pharmaceutical manufacturing facility in Panoli in Gujarat. The five-day detailed inspection was carried out during the period September 09, 2019 - September 13, 2019. The inspection confirmed the site to be compliant with the principles and guidelines of Current Good Manufacturing Practices (CGMP).
The inspection concluded with 'Zero' 483 observations from the auditors. The establishment inspection report received on December 12, 2019 has classified the facility under NAI (No Action Indicated) for CGMP compliance.
Hikal is engaged in R&D, manufacturing and marketing of fine chemicals for the Pharmaceutical and Agrochemical industries.
